Table 1.
Patient and Transplant Characteristics
| 1998–2009 | 2004–2009 | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| MAC | RIC | P | MAC | RIC | P | |
| N (%) | N (%) | N (%) | N (%) | |||
| N | 32 | 76 | 14 | 42 | ||
| Age (yrs) | ||||||
| <50 | 21 (66) | 22 (29) | 0.001 | 8 (57) | 9 (21) | 0.03 |
| 50 – <65 | 11 (34) | 48 (63) | 6 (43) | 29 (69) | ||
| ≥65 | 6 (8) | 4 (10) | ||||
| median (range) | 48 (27, 60) | 55 (36, 73) | 0.0001 | 47 (30, 58) | 57 (42, 73) | 0.0003 |
| Sex, Female | 10 (31) | 19 (25) | 0.63 | 3 (21) | 10 (24) | 1 |
| Pt-Donor Sex Match, M-F | 13 (41) | 25 (33) | 0.51 | 7 (50) | 17 (40) | 0.55 |
| Cell Source | ||||||
| PBSC | 18 (56) | 75 (99) | <0.001 | 14 (100) | 42 (100) | ---- |
| Donor Type | ||||||
| MUD | 13 (41) | 48 (63) | 0.04 | 9 (64) | 24 (57) | 0.76 |
| Disease Status | ||||||
| CR | 1 (3) | 6 (8) | 0.83 | 1 (7) | 4 (10) | 0.78 |
| nPR | 0 (0) | 1 (1) | ||||
| PR | 18 (56) | 36 (47) | 6 (43) | 26 (62) | ||
| SD | 5 (16) | 17 (22) | 3 (21) | 7 (17) | ||
| PD | 8 (25) | 16 (21) | 4 (29) | 5 (12) | ||
| No Prior Regimens | ||||||
| 1–3 | 17 (53) | 27 (36) | 0.13 | 6 (43) | 18 (43) | 1 |
| 4–9 | 15 (47) | 49 (64) | 8 (57) | 24 (57) | ||
| median (range) | 3 (1, 8) | 4 (1, 9) | 0.11 | 5 (1, 8) | 4 (1,9) | 0.76 |
| Purine Analogue Refractory | ||||||
| Yes | 22 (69) | 42 (55) | 0.13 | 12 (86) | 20 (48) | 0.02 |
| No | 10 (31) | 31 (41) | 2 (14) | 20 (48) | ||
| Not given | 0 (0) | 3 (4) | 0 (0) | 2 (5) | ||
| GVHD Prophylaxis | ||||||
| Sirolimus Containing | 12 (38) | 52 (68) | 0.005 | 11 (79) | 41 (98) | 0.04 |
| GVHD Prophylaxis | ||||||
| Sirolimus/Tacrolimus +MTX | 12 (38) | 50 (64) | ---- | 11 (79) | 39 (93) | |
| Sirolimus/MMF | 0 (0) | 2 (3) | 2 (5) | |||
| Tacrolimus ± MTX | 6 (19) | 7 (9) | 3 (21) | 1 (2) | ||
| CSA + Other | 5 (16) | 16 (21) | ||||
| T Cell Depletion | 9 (28) | 0 (0) | ||||
| Year of transplant, >=2004 | 14 (44) | 42 (55) | 0.3 | |||
MAC: Myeloablative Conditioning; RIC: Reduced Intensity Conditioning